It’s been wonderful attending @ILCAnews and connecting in person with many friends and colleagues for the first time in 2+ years. See many of you @AASLDtweets #TLM22 in @washingtondc in November and certainly #ILCA23 in Amsterdam next September! #ILCA22
@ILCAnews @acv69cardenas very rational recommendations for prevention and risk mitigation of variceal bleeding in the setting of unresectable #HCC (particularly if being considered for #atezolizumab #bevacizumab) #ILCA22
@ILCAnews @acv69cardenas LSM>15 kPa+ plt <150k highly suggests CSPH. Start #carvedilol which reduces risk of death and decompensation. If doesn’t meet these criteria, doesn’t require EGD before initiation of #atezolizumab #bevacizumab for uHCC #ILCA22
@ILCAnews congratulations to @bruixj on receiving the Nelson Fausto award from the association he was instrumental in founding. @bruixj you are our North Star when it comes to evidence base, patient centered #HCC research and care! #ilca22 @BCLC_group @liverunitclinic
@ILCAnews @MacarullaTeresa
3 @US_FDA & EMA approved #CCA targeted rx #pemigatinib #ivosidenib #dabrafenib #trametinib Unfortunately #NGS which identifies targeted rx underutilized & often not reimbursed. #NGS endorsed by @myESMO for all #CCA #ILCA22 @CCA_Alliance @curecc
@ILCAnews @MacarullaTeresa ESCAT alterations portend a more favorable prognosis in cholangiocarcinoma. NGS analysis to test for these alterations may be expensive and challenging. @CCA_Alliance @curecc #ILCA22
@ILCAnews @JesusMBanales >50% cholangiocarcinomas are of unclear etiology. Rest may be related to tobacco, T2DM, alcohol and #NAFLD. @curecc @CCA_Alliance #ILCA22
@EASLnews An “aggressive” tumor board roster debating surgery, radioembolization and maybe even more for a BCLC C non cirrhotic patient with branch portal vein invasion! @bruixj @LorenzaRimassa @docamitgs @sapisochin #ILCA22
@Zucmanrossi reports @ILCAnews had best year ever with solid growth and truly global membership. Good uptake of non physicians including nurses, advanced practice providers and patient advocates @augustoNYC @laurakulik1 @LorenzaRimassa #ILCA22
@ILCAnews Dr. Tim Meyer @ucl version of his algorithm for #HCC systemic therapy sequencing. I am including @DrElkhoueiry version presented yesterday for comparison (factors in pt characteristics) Some differences due to data gaps and expert opinion #ilca22
@ILCAnews Dr. Meyer @ucl cites some examples of “markers” of #HCC response to systemic rx or lacktherof
⬆️AFP and #ramucirumab in 2L
#HCV pos and #sorafenib (maybe)
#NAFLD and potential resistance to ICIs @CancerInflam
Non viral hepatitis and #durvalumab #tremelimumab #ilca22
@ILCAnews Drs. Tim Meyer @ucl and Katie Kelley @UCSFMedicine review the current state of #HCC systemic therapy #sorafenib #lenvatinib #cabozantinib #pembrolizumab #atezolizumab #bevacizumab #durvalumab #tremelimumab #camrelizumab #tislelizumab #rivoceranib #ilca22
@ILCAnews I have a lot to learn about machine learning. The end. #ilca22
@ILCAnews nice discussion of early stage disease. Important reminder that all solitary #HCC lesions in absence of MVI/EHS regardless of size are BCLC A and deserve consideration for R0 resection @riadsalemIR @sapisochin @ma5RN #ILCA22 #livertwitter
